WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD. Wanbangde Pharmaceutical Holding Group Co., Ltd. Share Price
Equities
002082
CNE000001P94
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.87 CNY | +3.62% |
|
+15.13% | -23.91% |
| Sales 2022 | 1.79B 247M 19.67B | Sales 2023 | 1.54B 213M 16.98B | Capitalization | 3.91B 541M 43.1B |
|---|---|---|---|---|---|
| Net income 2022 | 93M 12.86M 1.02B | Net income 2023 | 49M 6.78M 539M | EV / Sales 2022 | 3.25 x |
| Net Debt 2022 | 397M 54.87M 4.37B | Net Debt 2023 | 748M 103M 8.24B | EV / Sales 2023 | 3.02 x |
| P/E ratio 2022 |
58.8
x | P/E ratio 2023 |
80
x | Employees | 1,569 |
| Yield 2022 |
1.36% | Yield 2023 |
-
| Free-Float | 44.52% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.62% | ||
| 1 week | +15.13% | ||
| Current month | -1.81% | ||
| 1 month | -1.81% | ||
| 3 months | -14.26% | ||
| 6 months | -21.20% | ||
| Current year | -23.91% |
1 week
4.33
4.88
1 month
4.075.16
Current year
3.706.65
1 year
3.708.07
3 years
3.7017.35
5 years
3.7017.67
10 years
3.7028.89
| Managers | Title | Age | Since |
|---|---|---|---|
Shou Ming Zhao
CEO | Chief Executive Officer | 60 | 13/07/17 |
Tong Ke Liu
BRD | Director/Board Member | 59 | 13/07/17 |
Jian Jiang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hu Gen Wang
CHM | Chairman | 75 | 13/07/17 |
Shou Ming Zhao
CEO | Chief Executive Officer | 60 | 13/07/17 |
Tong Ke Liu
BRD | Director/Board Member | 59 | 13/07/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4.87 | +3.62% | 6,246,600 |
| 26/04/24 | 4.7 | +1.95% | 9,856,810 |
| 25/04/24 | 4.61 | +1.99% | 5,238,908 |
| 24/04/24 | 4.52 | +3.67% | 4,751,561 |
| 23/04/24 | 4.36 | +3.07% | 4,096,200 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -23.91% | 397M | |
| +20.81% | 43.34B | |
| +23.10% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -10.51% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.22B |
- Stock Market
- Equities
- 002082 Stock
